RU2015154737A - Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности - Google Patents
Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности Download PDFInfo
- Publication number
- RU2015154737A RU2015154737A RU2015154737A RU2015154737A RU2015154737A RU 2015154737 A RU2015154737 A RU 2015154737A RU 2015154737 A RU2015154737 A RU 2015154737A RU 2015154737 A RU2015154737 A RU 2015154737A RU 2015154737 A RU2015154737 A RU 2015154737A
- Authority
- RU
- Russia
- Prior art keywords
- neuregulin
- mammal
- day
- pump
- amount
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title claims 4
- 206010019280 Heart failures Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 26
- 102000014413 Neuregulin Human genes 0.000 claims 23
- 108050003475 Neuregulin Proteins 0.000 claims 23
- 241000124008 Mammalia Species 0.000 claims 17
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003203 everyday effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000005240 left ventricle Anatomy 0.000 claims 2
- 230000003319 supportive effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826433P | 2013-05-22 | 2013-05-22 | |
| US61/826,433 | 2013-05-22 | ||
| PCT/CN2014/078154 WO2014187342A1 (en) | 2013-05-22 | 2014-05-22 | Extended Release of Neuregulin for Treating Heart Failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015154737A true RU2015154737A (ru) | 2017-06-27 |
| RU2015154737A3 RU2015154737A3 (cg-RX-API-DMAC7.html) | 2018-04-26 |
Family
ID=51932900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015154737A RU2015154737A (ru) | 2013-05-22 | 2014-05-22 | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10098834B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3895724B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6568052B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102578135B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105611955A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014270882B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015029293A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2911848A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2743617T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015154737A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014187342A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CA2884051A1 (en) | 2012-10-08 | 2014-04-17 | Zensun (Shanghai) Science & Technology, Ltd. | Compositions and methods for treating heart failure in diabetic patients |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN111407881A (zh) * | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| CN111840517A (zh) * | 2019-04-28 | 2020-10-30 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于长效预防、治疗或延迟心脏损伤的方法 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| WO1989001489A1 (en) | 1987-08-10 | 1989-02-23 | Commonwealth Scientific And Industrial Research Or | Control of angiogenesis and compositions and methods therefor |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| GB9107566D0 (en) | 1991-04-10 | 1991-05-29 | Ludwig Inst Cancer Res | Glial mitogenic factors,their preparation and use |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US6087323A (en) | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| FI943071L (fi) | 1993-06-24 | 1994-12-25 | Takeda Chemical Industries Ltd | Anti-endoteliiniainetta pysyvästi vapauttava valmiste |
| US6750196B1 (en) | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US5941868A (en) | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| JP4515542B2 (ja) | 1997-02-10 | 2010-08-04 | ジェネンテック， インコーポレイテッド | ヒレグリン変異体 |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| CA2306228A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| MXPA02008239A (es) | 2000-02-28 | 2004-08-12 | Decode Genetics Ehf | Gen humano de la esquizofrenia. |
| US20010041869A1 (en) | 2000-03-23 | 2001-11-15 | Causey James D. | Control tabs for infusion devices and methods of using the same |
| US20050277887A1 (en) * | 2000-05-08 | 2005-12-15 | Joel Douglas | Micro infusion drug delivery device |
| EP2357004B1 (en) | 2000-05-23 | 2016-10-12 | CeNeS Pharmaceuticals, Inc. | NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods |
| US6589229B1 (en) | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
| WO2002024889A2 (en) | 2000-09-12 | 2002-03-28 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Optimized cardiac contraction through differential phosphorylation of myosin |
| US6482624B2 (en) | 2000-11-14 | 2002-11-19 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| AU2002222471A1 (en) | 2000-12-11 | 2002-06-24 | Yeda Research And Development Co..Ltd. | Inhibitory agents derived from specific growth factors |
| RU2180843C1 (ru) | 2001-02-19 | 2002-03-27 | Новокузнецкий государственный институт усовершенствования врачей | Способ профилактики повторного инфаркта миокарда |
| CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| CA2461661A1 (en) | 2001-10-19 | 2003-05-01 | Maxim Pharmaceuticals, Inc. | Use of histamine to treat liver disease |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1498656A (zh) | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
| US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
| CA2506630A1 (en) | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| JP2007505158A (ja) | 2003-05-21 | 2007-03-08 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害 |
| US20050065760A1 (en) | 2003-09-23 | 2005-03-24 | Robert Murtfeldt | Method for advising patients concerning doses of insulin |
| CN1715926B (zh) | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | 神经调节蛋白突变体的应用 |
| CN1743006A (zh) | 2004-09-02 | 2006-03-08 | 上海泽生科技开发有限公司 | Mapk抑制剂的新用途及组合物 |
| CN1743005A (zh) | 2004-09-02 | 2006-03-08 | 上海泽生科技开发有限公司 | Pi3－k抑制剂的新用途及组合物 |
| WO2006108208A1 (en) | 2004-10-14 | 2006-10-19 | Adventures Plus Pty Ltd | A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals |
| US20060160062A1 (en) | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| US20070141548A1 (en) | 2005-03-11 | 2007-06-21 | Jorg Kohl | Organ transplant solutions and method for transplanting organs |
| US7641649B2 (en) | 2005-05-06 | 2010-01-05 | Medtronic Minimed, Inc. | Reservoir support and method for infusion device |
| CN100361709C (zh) | 2005-08-30 | 2008-01-16 | 山东省生物药物研究院 | 一种对生命活性物质有保护作用的糖类组合 |
| CN1768859A (zh) | 2005-10-24 | 2006-05-10 | 天津大学 | 基于醛基的微粒表面多重生物功能因子组装方法 |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| CN101394861A (zh) | 2005-12-30 | 2009-03-25 | 上海泽生科技开发有限公司 | 纽兰格林持续给药能改善心脏功能 |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CN101310779A (zh) * | 2007-05-25 | 2008-11-26 | 上海泽生科技开发有限公司 | 包含神经调节蛋白的装置及药物制剂 |
| CN101310766B (zh) | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| EP3632459A1 (en) | 2008-07-17 | 2020-04-08 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
| WO2010060266A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin and cardiac stem cells |
| EP3087998B1 (en) * | 2009-06-09 | 2019-09-04 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin based methods for treating heart failure |
| ES2748886T3 (es) * | 2009-06-09 | 2020-03-18 | Zensun Shanghai Science & Tech Co Ltd | Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| DK2544537T3 (en) | 2010-03-10 | 2017-08-28 | Cempra Pharmaceuticals Inc | PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS |
| AU2011224341B2 (en) * | 2010-03-10 | 2014-07-10 | The University Of Florida Research Foundation, Inc. | Modulating aquaporins with relaxin |
| EP2555788B1 (en) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
| CN108420827A (zh) | 2010-07-22 | 2018-08-21 | 雷文制药有限公司 | 包含磁偶极子稳定化溶液的组合物及其用途 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| CA2884051A1 (en) | 2012-10-08 | 2014-04-17 | Zensun (Shanghai) Science & Technology, Ltd. | Compositions and methods for treating heart failure in diabetic patients |
| CA2904055A1 (en) | 2013-03-06 | 2014-09-12 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| CN104337813A (zh) | 2013-07-23 | 2015-02-11 | 上海泽生科技开发有限公司 | 使用维生素b组合物促进胃肠系统动力的方法 |
| CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| AT521173B1 (de) | 2018-06-27 | 2019-11-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegewerkzeug mit Distanzelement |
-
2014
- 2014-05-22 CA CA2911848A patent/CA2911848A1/en not_active Abandoned
- 2014-05-22 EP EP21165529.5A patent/EP3895724B1/en active Active
- 2014-05-22 KR KR1020227002787A patent/KR102578135B1/ko active Active
- 2014-05-22 BR BR112015029293A patent/BR112015029293A2/pt not_active Application Discontinuation
- 2014-05-22 JP JP2016514266A patent/JP6568052B2/ja active Active
- 2014-05-22 AU AU2014270882A patent/AU2014270882B2/en active Active
- 2014-05-22 KR KR1020237030815A patent/KR20230132635A/ko not_active Ceased
- 2014-05-22 US US14/892,183 patent/US10098834B2/en active Active
- 2014-05-22 ES ES14800519T patent/ES2743617T3/es active Active
- 2014-05-22 EP EP14800519.2A patent/EP2999499B1/en active Active
- 2014-05-22 RU RU2015154737A patent/RU2015154737A/ru not_active Application Discontinuation
- 2014-05-22 CN CN201480038610.9A patent/CN105611955A/zh active Pending
- 2014-05-22 KR KR1020157033291A patent/KR102357275B1/ko active Active
- 2014-05-22 EP EP19186339.8A patent/EP3610905B1/en active Active
- 2014-05-22 CN CN202011061572.2A patent/CN112168953A/zh active Pending
- 2014-05-22 WO PCT/CN2014/078154 patent/WO2014187342A1/en not_active Ceased
-
2018
- 2018-09-10 US US16/126,852 patent/US11179323B2/en active Active
-
2019
- 2019-05-30 AU AU2019203799A patent/AU2019203799B2/en active Active
- 2019-06-11 JP JP2019108985A patent/JP2019172689A/ja active Pending
-
2021
- 2021-10-25 US US17/510,271 patent/US12208158B2/en active Active
-
2024
- 2024-12-19 US US18/988,434 patent/US20250360078A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015154737A (ru) | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности | |
| JP2016520089A5 (cg-RX-API-DMAC7.html) | ||
| AR071810A1 (es) | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. | |
| JP2015057427A5 (cg-RX-API-DMAC7.html) | ||
| RU2018123666A (ru) | Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина | |
| RU2015132860A (ru) | Композиции инсулинов длительного действия | |
| NZ598085A (en) | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | |
| JP2014528901A5 (cg-RX-API-DMAC7.html) | ||
| WO2009093880A3 (en) | Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| IL274098B2 (en) | Glp-2 analogs and peptibodies for administration before during, or after surgery | |
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2013519363A5 (cg-RX-API-DMAC7.html) | ||
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| BR112015022565A2 (pt) | composições e métodos para aumentar o potencial terapêutico das células tronco | |
| RU2012122649A (ru) | Способ диагностики ишемии миокарда у больных кардиальным синдромом х | |
| RU2007117876A (ru) | Способ лечения поверхностного рака мочевого пузыря | |
| RU2016138790A (ru) | Композиции на основе сиалированных гликопротеинов и их применение | |
| EA201101663A1 (ru) | Ковалентный конъюгат полиэтиленгликоля с гранулоцитарным колониестимулирующим фактором человека | |
| ES2553590T3 (es) | Método de reparación y regeneración renal y el tratamiento de nefropatía diabética | |
| RU2008150401A (ru) | Способ лечения бабезиоза собак | |
| RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
| EA201591737A1 (ru) | Доставка sdf-1 для лечения ишемизированной ткани |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200730 |